Cenomed

Cenomed is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics for Central Nervous System (CNS) disorders. The company's pipeline targets significant unmet medical needs in psychiatry and neurology, including cognitive impairment associated with schizophrenia (CIAS) and post-traumatic stress disorder (PTSD). Their lead candidate, CM-2302, is a potent and selective alpha-7 nicotinic acetylcholine receptor positive allosteric modulator designed to improve cognitive function. Cenomed utilizes its expertise in medicinal chemistry to develop drugs that modulate neurotransmitter systems with high specificity. The company aims to provide transformative treatments for patients suffering from debilitating neurological and psychiatric conditions.